GlobeNewsWire
06 Aug 2026, 02:33 UTC · 13w ago
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
Impact · against what's priced in
Braveheart Bio (BRVE) has successfully raised $382.5 million through an upsized IPO, significantly reducing its immediate liquidity risk and funding the development of BHB-1893. For Goldman Sachs (GS), the event provides minor fee-based revenue that is unlikely to move the needle on its overall valuation.
- BRVE+0.70
No priced-in read yet
- In context
The pricing of an upsized IPO at $18.00 per share provides $382.5 million in gross proceeds, establishing a public valuation and securing critical capital for the development of BHB-1893.
Read from the article alone
Top 1 mover · tap to explore
